Patents by Inventor Weijiang Zhang

Weijiang Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8541597
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: September 24, 2013
    Assignee: Theravance, Inc.
    Inventors: Weijiang Zhang, Pierre-Jean Colson
  • Patent number: 8455530
    Abstract: The invention provides a crystalline freebase form of 4?-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3?-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: June 4, 2013
    Assignee: Theravance, Inc.
    Inventors: Robert S. Chao, Weijiang Zhang
  • Publication number: 20130115194
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 9, 2013
    Inventors: Daniel D. LONG, Robert Murray MCKINNELL, Lan JIANG, Mandy LOO, Kassandra LEPACK, Lori Jean VAN ORDEN, Gavin OGAWA, Xiaojun HUANG, Weijiang ZHANG
  • Publication number: 20120309805
    Abstract: The invention provides a crystalline freebase form of 4?-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3?-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.
    Type: Application
    Filed: March 2, 2012
    Publication date: December 6, 2012
    Applicant: THERAVANCE, INC.
    Inventors: Robert S. Chao, Weijiang Zhang
  • Publication number: 20120209008
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Application
    Filed: April 25, 2012
    Publication date: August 16, 2012
    Applicant: THERAVANCE, INC.
    Inventors: Weijiang Zhang, Pierre-Jean Colson
  • Patent number: 8188294
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: May 29, 2012
    Assignee: Theravance, Inc.
    Inventors: Weijiang Zhang, Pierre-Jean Colson
  • Patent number: 8153675
    Abstract: The invention provides a crystalline freebase form of 4?-{2-ethoxy-4-ethyl-5-[((S) -2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3?-fluorobiphenyl-2 -carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: April 10, 2012
    Assignee: Theravance, Inc.
    Inventors: Robert S. Chao, Weijiang Zhang
  • Patent number: 8030502
    Abstract: This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: October 4, 2011
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, David Oare, Junning Lee, Weijiang Zhang
  • Publication number: 20110224272
    Abstract: The invention provides a crystalline freebase form of 4?-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3?-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.
    Type: Application
    Filed: November 11, 2010
    Publication date: September 15, 2011
    Applicant: THERAVANCE, INC.
    Inventors: Robert S. Chao, Weijiang Zhang
  • Publication number: 20110077411
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Application
    Filed: September 28, 2010
    Publication date: March 31, 2011
    Inventors: Weijiang Zhang, Pierre-Jean Colson, Gene Timothy Fass
  • Patent number: 7855221
    Abstract: The invention provides a crystalline freebase form of 4?-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3?-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: December 21, 2010
    Assignee: Theravance, Inc.
    Inventors: Robert S. Chao, Weijiang Zhang
  • Publication number: 20100204840
    Abstract: Methods and systems are described for controlling an expansion valve in large chiller refrigerant loops that employ a modified fuzzy logic control system that modulates an electric expansion valve for controlling cooling capacity.
    Type: Application
    Filed: May 22, 2008
    Publication date: August 12, 2010
    Applicant: CARRIER CORPORATION
    Inventors: Wenzhe Sun, Shufu Ding, Weijiang Zhang, Yongliang Hu
  • Patent number: 7772434
    Abstract: The invention provides a novel ?2 adrenergic receptor agonist in crystalline salt form. The invention also provides pharmaceutical compositions comprising the novel ?2 adrenergic receptor agonist in crystalline salt form, formulations containing the pharmaceutical compositions, methods of using the crystalline salt to treat diseases associated with ?2 adrenergic receptor activity, and processes useful for preparing such crystalline compounds.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: August 10, 2010
    Assignee: Theravance, Inc.
    Inventors: Ioanna Stergiades, Edward Yost, Cristin Hubbard, Weijiang Zhang
  • Publication number: 20100125150
    Abstract: The invention provides a novel ?2 adrenergic receptor agonist in crystalline salt form. The invention also provides pharmaceutical compositions comprising the novel ?2 adrenergic receptor agonist in crystalline salt form, formulations containing the pharmaceutical compositions, methods of using the crystalline salt to treat diseases associated with ?2 adrenergic receptor activity, and processes useful for preparing such crystalline compounds.
    Type: Application
    Filed: May 13, 2009
    Publication date: May 20, 2010
    Applicant: THERAVANCE, INC.
    Inventors: Ioanna Stergiades, Edward Yost, Cristin Hubbard, Weijiang Zhang
  • Publication number: 20100081697
    Abstract: The invention provides a crystalline freebase form of 4?-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3?-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 1, 2010
    Inventors: Robert S. Chao, Weijiang Zhang
  • Patent number: 7638639
    Abstract: This invention is directed to compounds of formula I: wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: December 29, 2009
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Adam Hughes, Yu-hua Ji, Li Li, Weijiang Zhang
  • Patent number: 7615566
    Abstract: This invention is directed to compounds of formula I: wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: November 10, 2009
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Adam Hughes, Yu-hua Ji, Li Li, Weijiang Zhang
  • Patent number: 7572918
    Abstract: Processes and intermediates for preparing substituted 4-amino-1-(pyridylmethyl)-piperidine and related compounds in high yield and high purity are described. The substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds prepared by the described processes are useful as muscarinic receptor antagonists.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: August 11, 2009
    Assignee: Theravance, Inc.
    Inventors: Matthew J Peterson, Junning Lee, Richard J Lee, Weijiang Zhang
  • Patent number: 7524880
    Abstract: The invention provides a crystalline naphthalene-1,5-disulfonic acid salt of 2-[(S)-1-(8-methylaminooctyl)pyrrolidin-3-yl]-2,2-diphenylacetamide or a solvate thereof. This invention also provides pharmaceutical compositions comprising the salt or prepared using the salt; processes and intermediates for preparing the salt; and methods of using the salt to treat a pulmonary disorder.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: April 28, 2009
    Assignee: Theravance, Inc.
    Inventors: Li Li, Robert Chao, Adam Hughes, Yu-Hua Ji, Davar Khossravi, Weijiang Zhang
  • Publication number: 20080161577
    Abstract: This invention is directed to compounds of formula I: wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.
    Type: Application
    Filed: January 30, 2008
    Publication date: July 3, 2008
    Inventors: Mathai Mammen, Adam Hughes, Yu-hua Ji, Li Li, Weijiang Zhang